Multimodal smoking cessation treatment combining repetitive transcranial magnetic stimulation, cognitive behavioral therapy, and nicotine replacement in veterans with posttraumatic stress disorder: A feasibility randomized controlled trial protocol

PLoS One. 2024 Sep 6;19(9):e0291562. doi: 10.1371/journal.pone.0291562. eCollection 2024.

Abstract

Tobacco-related deaths remain the leading cause of preventable death in the United States. Veterans suffering from posttraumatic stress disorder (PTSD)-about 11% of those receiving care from the Department of Veterans Affairs (VA)-have triple the risk of developing tobacco use disorder (TUD). The most efficacious strategies being used at the VA for smoking cessation only result in a 23% abstinence rate, and veterans with PTSD only achieve a 4.5% abstinence rate. Therefore, there is a critical need to develop more effective treatments for smoking cessation. Recent studies suggest the insula is integrally involved in the neurocircuitry of TUD. Thus, we propose a feasibility phase II randomized controlled trial (RCT) to study a form of repetitive transcranial magnetic stimulation (rTMS) called intermittent theta burst stimulation (iTBS). iTBS has the advantage of allowing for a patterned form of stimulation delivery that we will administer at 90% of the subject's resting motor threshold (rMT) applied over a region in the right post-central gyrus most functionally connected to the right posterior insula. We hypothesize that by increasing functional connectivity between the right post-central gyrus and the right posterior insula, withdrawal symptoms and short-term smoking cessation outcomes will improve. Fifty eligible veterans with comorbid TUD and PTSD will be randomly assigned to active-iTBS + cognitive behavioral therapy (CBT) + nicotine replacement therapy (NRT) (n = 25) or sham-iTBS + CBT + NRT (n = 25). The primary outcome, feasibility, will be determined by achieving a recruitment of 50 participants and retention rate of 80%. The success of iTBS will be evaluated through self-reported nicotine use, cravings, withdrawal symptoms, and abstinence following quit date (confirmed by bioverification) along with evaluation for target engagement through neuroimaging changes, specifically connectivity differences between the insula and other regions of interest.

Publication types

  • Randomized Controlled Trial
  • Clinical Trial Protocol

MeSH terms

  • Adult
  • Cognitive Behavioral Therapy* / methods
  • Combined Modality Therapy
  • Feasibility Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Smoking Cessation* / methods
  • Stress Disorders, Post-Traumatic* / therapy
  • Tobacco Use Cessation Devices
  • Tobacco Use Disorder / therapy
  • Transcranial Magnetic Stimulation* / methods
  • Veterans*

Grants and funding

J. Young is supported by VA Career Development Awards (CDA-1, CDA-2), Clinical Science Research and Development Service (CSR&D): 1 IK1 CX002187-01A1, 1 IK2 CX002610-01; Department of Veterans Affairs (VA) Mid-Atlantic Mental Illness Research, Education, and Clinical Center (MIRECC), Durham VA Health Care System; Duke University Department of Psychiatry & Behavioral Sciences; and Duke Interdisciplinary Studies Bass Connections. Z.-D. Deng and M. Dannhauer are supported by the National Institute of Mental Health (NIMH) Intramural Research Program (ZIAMH002955). J. Beckham is supported by a Senior Research Career Scientist Award (IK6BX003777) from VA Clinical Sciences Research and Development. The study sponsor did not or will not serve a significant role in study design, collection, management, analysis, or interpretation of data, writing of the report, decision to submit the report or ultimate authority over these activities. Public access of deidentified data will follow VA research standards. Trial results will be published by study team upon trial completion without restrictions or the use of professional writers.